Bydureon – data presented today at the 74th Scientific Sessions of the American Diabetes Association

Latest data demonstrate sustained results of Bydureon® treatment over six years with a second, retrospective study showing a higher likelihood of adherence with exenatide once-weekly vs. other GLP-1 therapies in type 2 diabetes patients (AstraZeneca)